Shares in AMN Healthcare Services, Inc. show a positive technical chart pattern over the medium term, which suggests that the rising trend should be followed. Investors have an opportunity to buy the stock and target the $ 120.
The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.
The company has a good ESG score relative to its sector, according to Refinitiv.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
As estimated by analysts, this group is among those businesses with the lowest growth prospects.
With a 2021 P/E ratio at 23.63 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.